Clene Inc. (NASDAQ: CLNN) has announced encouraging preclinical findings for its lead investigational therapy, CNM-Au8, in Parkinson’s disease. The data, presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City, highlight the drug’s potential to address key cellular and energetic deficits that drive disease progression (https://ibn.fm/EECHU).
The study showed that CNM-Au8 improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons—cells critically affected in Parkinson’s disease. These preclinical results align with positive energetic and metabolic effects observed in a previous Phase 2 Parkinson’s trial, reinforcing the therapeutic rationale for CNM-Au8.
CNM-Au8 is a gold nanocrystal suspension designed to enhance cellular energy production and protect neuronal function. Importantly, the treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in clinical trials for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
Clene plans to design a Phase 2 clinical study for Parkinson’s disease while continuing to advance its ALS and MS programs. The new data provide a mechanistic basis for targeting mitochondrial dysfunction and energetic failure, which are increasingly recognized as fundamental drivers of neurodegeneration in Parkinson’s. By improving mitochondrial health and reducing neuroinflammation, CNM-Au8 may offer a disease-modifying approach that addresses root causes rather than just symptoms.
The presentation at the Michael J. Fox Foundation meeting underscores the relevance of these findings, as the foundation is a leading advocate for accelerating therapies for Parkinson’s. The company’s stock symbol is CLNN, and additional information is available in its newsroom (https://ibn.fm/CLNN).
With no approved therapies that directly target mitochondrial health in Parkinson’s, CNM-Au8 represents a novel approach. If successful in upcoming trials, it could fill a critical gap in the treatment landscape. The preclinical data provide strong support for advancing CNM-Au8 into a larger, more definitive study.
